NTRK Gene Fusions: Finding the "Golden Ticket" in Oncology

Christina T. Loguidice
Published: Thursday, Jul 18, 2019
Dr. Benjamin P. Levy

Benjamin P. Levy, MD
Understanding the molecular mechanisms that drive each patient’s cancer is becoming increasingly important to better tailor care as more highly effective agents targeting specific actionable biomarkers are developed and brought to market. These emerging precision agents include tropomyosin receptor kinase (TRK) inhibitors, a class that has been shown to be highly effective in patients with NTRK gene fusions.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication